State Regulation, Explained: The 2026 Field Guide
What state regulation covers, why it matters in 2026, and the numbers decision-makers should know.
Executives keep asking the same question about state regulation. The state-by-state patchwork, from AI therapy bans to facility fees. This explainer sets out what the category actually covers, why it has moved to the center of policy & regulation strategy, and the numbers every decision-maker should have at hand.
What it covers
The state-by-state patchwork, from AI therapy bans to facility fees. In practice, that spans the vendors building the technology, the health systems and payers deploying it, and the regulators writing the rules around it. The category sits inside our broader Policy & Regulation coverage, and its daily developments stream into the live State Regulation feed.
Why it matters in 2026
Consider the current numbers: cMS launched a dedicated Office of Health Technology Products to steer AI and interoperability policy (our coverage).
Meanwhile, the FDA-CMS TEMPO pilot ties regulatory evaluation to real-world outcomes and Medicare coverage, with Dexcom as its first participant (our coverage).
Meanwhile, the proposed CY2027 fee schedule would create Medicare's first payment category for clinical AI software (our coverage).
What to watch next
Three signals will tell you where state regulation goes from here: the reimbursement decisions now moving through CMS and commercial payers, the consolidation pattern as larger platforms absorb point solutions, and the evidence base - peer-reviewed results increasingly separate durable categories from demo-ware.
The bottom line
The direction of travel is clear; the pace will be set by reimbursement and by the evidence base now accumulating. For the latest developments, follow our continuously updated State Regulation topic page.